The Weekly Recap 5/15/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, launch partnerships, receive regulatory approvals, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2).

Adialante

Granted its second U.S. patent covering the core technology behind its ability to image in MRIs using radio waves. The company is developing a new class of mobile MRI systems designed to deliver diagnostic-quality imaging directly to practices without the need for construction or major capital investment.

Angelini Ventures

Welcomed Samantha Wong, PhD, as Investment Analyst. Dr. Wong played a key role in the launch of EspressoLab by Angelini Ventures and the establishment of the company’s Singapore office.

Apreo Health

Announced the appointment of LSI Alumni David Amerson to its Board of Directors and a strategic investment from OSF Ventures, the corporate investment arm of OSF HealthCare. Amerson has over 30 years of leadership in the medical device industry, most recently serving as President of Interventional Urology at Teleflex following its $1.1B acquisition of NeoTract, where he was President and CEO.

BlueWind Medical

Closed $47.8M in financing in a combination of equity and debt. The company plans to use the proceeds to fund further commercialization for its Revi^® System, an implantable tibial neuromodulation platform that treats urgency urinary incontinence. 

Brainomix

Announced an expansion of its partnership with Boehringer Ingelheim to improve the care of patients with progressive pulmonary fibrosis. Building on results from the REVISE PPF study, the next phase, PROGRESS PPF, a prospective multicenter study, will focus on generating evidence of e-Lung’s clinical impact at scale, with deployments of e-Lung planned at numerous sites across the U.S.

Butterfly Medical

Closed a $21M upsized Series C fundraising round, including participation from the European Innovation Council (EIC), Junson Capital, MedVenture, and New Rhein Healthcare Investors. The company's flagship product, the Butterfly^® Medical device, is designed to restore natural urinary flow to provide significant, long-term relief from benign prostatic hyperplasia symptoms, thereby improving patients' quality of life.

CustomSurg

Welcomed Richard Keiser as its CTO. Keiser has over a decade of experience in medtech managing and directing software platforms and infrastructure, and looks to help the company advance its OrthoPlanner™, an FDA-cleared solution for pre-operative fracture planning. 

EndoShunt Medical

Welcomed LSI Alumni Catherine Kiani as a Board Observer on behalf of Elderberry Ventures. Kiani, backed by an involved advisory team with four decades of experience building, scaling, and defending medical device companies, brings a rare combination of legal, governance, and medical technology expertise. 

Endospan

Acquired by Artivion for an upfront purchase price of $135M. The acquisition comes on the heels of FDA approval for its NEXUS Aortic Arch Stent Graft, which was supported by the one-year results of the prospective multicenter TRIOMPHE investigational device exemption study. 

HeartBeam

Entered into an agreement with Atelier Health to expand its commercial footprint into Southern California. Combined with its recent partnership with ClearCardio, the partnership with Atelier establishes the company’s initial presence across Southern California, the New York metro, Dallas, and South Florida, creating a foundation for broader national growth.

LightHearted AI

Received backing from LSI Alumni Draper Associates as the company advances its mission to prevent 10 million heart-related deaths by 2030 and reinvent cardiac diagnostics. Its silicon and photonics platform captures cardiovascular signals, including blood pressure and ECG, from meters away without contact and decodes them in real time using AI.

Mobia Medical

Announced the pricing of its initial public offering of 10M shares of its common stock at a public offering price of $15 per share. The gross proceeds from the offering, before deductions, are expected to be approximately $150M, excluding any exercise of the underwriters’ option to purchase additional shares.

NeuWire Medical

Appointed LSI Alumni Ramin Mousavi as Executive Chairman as the company advances toward an FDA pivotal study for post-stroke rehabilitation. Mousavi joins the company following his role as President, CEO, and board member of CathWorks, where he led the company through a strategic partnership, global co-promotion agreement, landmark clinical trial, and eventual acquisition by Medtronic.

OrthoPreserve

Received funding from Fund That Tiger, a Clemson–based venture capital fund.that invests exclusively in Clemson University alumni-led startups and university-born technologies. The company is developing an artificial meniscus replacement implant to restore knee joint function, focusing on relieving pain and impairment, quick recovery, and reducing the risk of arthritis and knee replacements in patients with previous meniscus injuries.

Perimeter Medical Imaging

Closed its "LIFE" offering, raising approximately C$14.4M in aggregate proceeds alongside a concurrent debenture offering. The funding positions the company for the U.S. commercial launch of Claire™, the first FDA-approved AI-enabled, adjunctive imaging device for intraoperative breast cancer margin assessment.

RIVANNA

Received FDA 510(k) clearance for the Accuro^® XV Diagnostic Ultrasound System, including BoneEnhance^®, an image segmentation module for enhanced bone visualization, and CADe/x, the first computer-aided detection algorithm for automated fracture identification derived from volumetric ultrasound imaging. The clearance comes as the company accelerates development of AI-enabled capabilities for the platform, with both BoneEnhance and CADe/x being trained and validated through an ongoing eight-site clinical study.

UroMems

Raised a $60M strategic investment from LSI Alumni Ajax Health, financed entirely by the Ajax Health Fund I. The financing will support UroMems through the completion of its ongoing SOPHIA2 clinical trial of the UroActive® smart implant in 21 U.S. and French investigational centers in preparation for regulatory submission to both the U.S. and European markets.

Vicarious Surgical

Completed a full-day synthetic abdominal model lab with its surgical robot. The lab demonstrated sustained system performance and continued procedural workflow progression for its Vicarious Surgical System, keeping the company on track for a design freeze by the end of 2026.

ViCentra

Announced the commercial launch of its new smartphone-controlled hybrid closed loop system, with first deliveries in Germany and the Netherlands planned for later this summer. The system combines the Kaleido insulin patch pump, Diabeloop’s self-learning DBLG2 algorithm, and the Dexcom G7 CGM system to deliver a more streamlined, discreet, and personalized diabetes management experience.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.